

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

accept change(s) to the agreed paediatric investigation plan and to the deferral.

MHRA-101283-PIP01-23-M01

### **Scope of the Application**

#### **Active Substance(s)**

Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues

#### **Condition(s)**

Treatment of congenital haemophilia A, Treatment of congenital haemophilia B.

#### **Pharmaceutical Form(s)**

Solution for injection

#### **Route(s) of Administration**

SUBCUTANEOUS USE

#### **Name / Corporate name of the PIP applicant**

Sanofi B.V.

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, Sanofi B.V. submitted to the licensing authority on 01/12/2023 15:01 GMT an application for a

The procedure started on 25/03/2024 13:27 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

## Final Decision Letter

MHRA-101283-PIP01-23-M01

Of 19/04/2024 09:06 BST

On the adopted decision for Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (MHRA-101283-PIP01-23-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a for Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues, Solution for injection , SUBCUTANEOUS USE .

This decision is addressed to Sanofi B.V., Paasheuvelweg 25, Amsterdam, NETHERLANDS, 1105 BP

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Condition 1 Treatment of congenital haemophilia A The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 1 year of age. Pharmaceutical form(s): Solution for injection Route(s) of administration: SUBCUTANEOUS USE Reason for granting waiver: On the grounds the specific medicinal product is likely to be unsafe. Condition 2 Treatment of congenital haemophilia B. The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 1 year of age. Pharmaceutical form(s): Solution for injection Route(s) of administration: SUBCUTANEOUS USE Reason for granting waiver: On the grounds the specific medicinal product is likely to be unsafe.

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Condition 1: Treatment of congenital haemophilia A. Condition 2 Treatment of congenital haemophilia B.

## 2.2 Indication(s) targeted by the PIP:

Condition 1 Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in children aged  $\geq 1$  year with severe congenital haemophilia A, including patients who express neutralising antibodies to exogenous factor VIII substitution. Condition 2 Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in children aged  $\geq 1$  year with severe congenital haemophilia B, including patients who express neutralising antibodies to exogenous factor IX substitution.

## 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

For both Conditions: The paediatric population from 1 year to less than 18 years of age.

## 2.4 Pharmaceutical Form(s):

For both Conditions: Solution for injection

## 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	1	Same study for both Conditions: Study 1 (9000727) Dose range-finding juvenile toxicity study to evaluate the potential toxicity of fitusiran in neonate Sprague-Dawley rats.
Clinical Studies	7	Same studies for both Conditions: Study 2 (ALN-AT3SC-003, Sanofi Genzyme EFC14768) Randomised, open-label, parallel group study comparing fitusiran to on-demand bypassing agents (BPA) in patients from 12 years to less than 18 years of age (and adults) with haemophilia A or B who express inhibitors to replacement factor therapy and who receive on demand treatment for bleeding episodes. The objectives are to evaluate efficacy, safety, PK, PD and HRQoL. Study 3 (ALN-AT3SC-004; Sanofi Genzyme

		<p>EFC14769) Randomised, open-label, parallel group study comparing fitusiran to on-demand Factor VIII or IX only in patients from 12 years to less than 18 years of age (and adults) with haemophilia A or B without inhibitors to replacement factor therapy and who receive on demand treatment for bleeding episodes. The objectives are to evaluate efficacy, safety, PK, PD and HRQoL. Study 4 (ALN-AT3SC-009; Sanofi Genzyme EFC15110) Open-label, single-arm, one-way crossover study initiated for haemophilia A and B patients from 12 years to less than 18 years of age (and adults) with and without inhibitors, previously treated with prophylactic Factor VIII or Factor IX or bypassing agents (BPAs). Intra patient comparison of patients treated with fitusiran to previous standard of care prophylaxis treatment (run-in period). The objective of the study is to assess the efficacy and safety of fitusiran administration as prophylaxis.</p>
<b>Extrapolation, Modeling &amp; Simulation Studies</b>	0	Not applicable.
<b>Other Studies</b>	0	<p>Clinical Studies continued: Study 5 (LTE15174) Open-label extension study to studies ALN-AT3SC-003 (EFC14768), ALN-AT3SC-004 (EFC14769) and ALN-AT3SC-009 (EFC15110). The main objective of the study is to assess the efficacy and safety of long-term administration of fitusiran. Study 6 (ATLAS Paediatrics Study Part A, EFC15467) Open-label, non-comparative study in patients from 1 year to less than 12 years of age with severe haemophilia A or B who express inhibitors to replacement factor therapy and who receive on demand treatment for bleeding episodes. The objectives are to evaluate safety, PK and PD. Study 7 (ATLAS Non - Interventional Paediatric Study) This study was deleted during procedure MHRA-101283-PIP01-23-M01. Study 8 (ATLAS Paediatrics Study Part B, EFC17905) Open-label,</p>

		<p>single group, two arm study to evaluate the efficacy and safety of fitusiran prophylaxis in paediatric subjects ages 1 year to less than 12 years with severe haemophilia A or B, with or without inhibitors, previously receiving factor or BPA treatments. Study 9 (EFC17574, ATLAS NEO) (This study was added during procedure MHRA-101283-PIP01-23-M01) Open-label, single-arm, one-way crossover study to evaluate the efficacy and safety of fitusiran prophylaxis in male participants aged from 12 years to less than 18 years of age (and adults) with severe haemophilia A or B, with or without inhibitory antibodies to Factor VIII or IX, who have switched from their prior Clotting Factor Concentrate (CFC) or Bypassing Agents (BPA) standard of care (SOC) treatment.</p>
<b>Other Measures</b>	0	Not applicable.

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	Yes
<b>Date of completion of the paediatric investigation plan:</b>	30/06/2030
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes